Street Calls of the Week
DUBLIN - Investment firm Citadel Group has disclosed a 1.38% stake in Mural Oncology plc, according to a regulatory filing published Thursday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 239,341 shares representing a 1.38% interest in the oncology company as of October 15. This includes 226,041 owned and controlled shares and 13,300 shares through stock-settled derivatives.
The filing also reveals Citadel maintains short positions equivalent to 1.17% of Mural Oncology’s shares, primarily through stock-settled derivatives including options.
Transaction details show Citadel executed multiple trades on October 15, purchasing a total of 11,158 common shares at prices ranging from $2.08 to $2.09 per share. The firm also sold 5,195 shares during the same period at similar price points.
The disclosure includes information about Citadel’s options positions, with various call and put options expiring between October 2025 and January 2027, with strike prices ranging from $2.50 to $7.50.
Mural Oncology plc is listed on the Irish stock exchange with common stock trading under ISIN IE000LK2BOB4.
The information was disclosed in a Form 8.3 filing, which is required under Irish takeover regulations when an entity holds interests in relevant securities representing 1% or more of a company that may be involved in a potential transaction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.